Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05746598
Status:
RECRUITING
Last Update Posted:
2023-02-28
First Post:
2023-02-08
Brief Title:
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Sponsor:
Ain Shams University
Organization:
Ain Shams University
Study Overview
Official Title:
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lung cancer is the leading cause of death worldwide with non-small-cell lung cancer NSCLC being the most common histotype according to the global cancer observatory 2022 A variety of therapeutic options for advancedmetastatic non-oncogene-addicted NSCLC have recently been approved based on their impact on patient outcomes in terms of survival and safety profile Current guidelines advocate for personalized treatment options based on molecular and immunologic characteristics which drives the physicians decision toward tailored oncology
In the last two to three decades hundreds of cancer biological prognostic markers for non-small cell lung cancer have been proposed Although they have shown a potential in this field validation studies are still required and to date there is in sufficient evidence to recommend the routine clinical use of any of these putative biomarkers Therefore the discovery of robust prognostic andor predictive biomarkers in patients with non-small cell lung cancer is imperative for advancing treatment strategies for the disease and improving patient care
In the last two to three decades hundreds of cancer biological prognostic markers for non-small cell lung cancer have been proposed Although they have shown a potential in this field validation studies are still required and to date there is in sufficient evidence to recommend the routine clinical use of any of these putative biomarkers Therefore the discovery of robust prognostic andor predictive biomarkers in patients with non-small cell lung cancer is imperative for advancing treatment strategies for the disease and improving patient care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None